Black Diamond Therapeutics (BDTX) investor relations material

Executive summary

• Silevertinib advanced to Phase 2 trials for EGFRm NSCLC and EGFRvIII+ GBM, with promising efficacy and safety data presented at ASCO 2026, including no de novo brain metastases and an 86% CNS objective response rate in NSCLC patients with baseline brain metastases.

• Silevertinib is positioned as a potential best-in-class brain-penetrant EGFR inhibitor, with pivotal development path updates and FDA feedback expected in Q4 2026.

• No product revenue generated; operations funded by equity offerings and a $70M upfront payment from Servier for BDTX-4933 licensing.

• Net loss of $18.9M for the six months ended June 30, 2026, compared to net income of $46.0M in the prior year period, reflecting the absence of new licensing revenue.

• Phase 2 trial in combination with temozolomide for EGFRvIII+ glioblastoma is enrolling, with randomized portion initiation planned for Q4 2026.

Financial highlights

• Cash, cash equivalents, and investments totaled $110.5M as of June 30, 2026, expected to fund operations into the second half of 2028.

• Research and development expenses decreased to $14.4M for the six months ended June 30, 2026, from $19.8M year-over-year, mainly due to lower NSCLC trial costs and BDTX-4933 deprioritization.

• General and administrative expenses were $8.9M for the six months ended June 30, 2026, down slightly from $9.1M year-over-year; Q2 2026 G&A expenses were $4.7M, up from $4.1M in Q2 2025.

• Net cash used in operations was $8.0M for Q2 2026, compared to $9.2M in Q2 2025.

• Net loss for Q2 2026 was $9.9M, compared to $10.5M in Q2 2025.

Outlook and guidance

• Cash runway projected into the second half of 2028, but additional capital will be needed for regulatory approval and commercialization activities.

• Update on pivotal development path for silevertinib in NSCLC and FDA feedback anticipated in Q4 2026.

• Ongoing efforts to secure partnerships for silevertinib pivotal development and to realize milestone and royalty payments from Servier.

• Randomized portion of the Phase 2 GBM trial expected to begin in Q4 2026.